BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19528278)

  • 1. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.
    Bulitta JB; Landersdorfer CB; Kinzig M; Holzgrabe U; Sorgel F
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3462-71. PubMed ID: 19528278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective.
    Rodríguez-Gascón A; Aguirre-Quiñonero A; Canut-Blasco A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020; 38(7):306-311. PubMed ID: 32085928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens.
    James NC; Donn KH; Collins JJ; Davis IM; Lloyd TL; Hart RW; Powell JR
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1860-3. PubMed ID: 1952858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Kinzig M; Landersdorfer CB; Holzgrabe U; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2927-36. PubMed ID: 21402834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the pharmacokinetics of oral cefuroxime axetil in dogs.
    Albarellos GA; Passini SM; Lupi MP; Aramayona S; Lorenzini PM; Montoya L; Landoni MF
    J Vet Pharmacol Ther; 2020 May; 43(3):297-302. PubMed ID: 32157713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Perry CM; Brogden RN
    Drugs; 1996 Jul; 52(1):125-58. PubMed ID: 8799689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers.
    Thønnings S; Jensen KS; Nielsen NB; Skjønnemand M; Hansen DS; Lange KHW; Frimodt-Møller N
    J Med Microbiol; 2020 Mar; 69(3):387-395. PubMed ID: 31958049
    [No Abstract]   [Full Text] [Related]  

  • 12. Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.
    Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of cefuroxime-axetil in the treatment of respiratory tract infections. Bacteriological and pharmacological data].
    Bergogne-Berezin E; Vallée E; Muller-Serieys C
    Therapie; 1991; 46(4):333-7. PubMed ID: 1948811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring antibiotic levels in otitis media.
    Thoroddsen E
    Ear Nose Throat J; 1998 Jun; 77(6 Suppl):13-5. PubMed ID: 9674329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefuroxime axetil suspension in infants and children.
    Powell DA; James NC; Ossi MJ; Nahata MC; Donn KH
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2042-5. PubMed ID: 1759825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killing kinetics of cefuroxime axetil against Haemophilus influenzae in an in-vitro model simulating serum concentration profiles after oral administration.
    Bingen E; Lambert-Zechovsky N; Doit C; Duvignaud P; Georges D; Mariani-Kurkdjian P
    J Antimicrob Chemother; 1991 Oct; 28(4):533-6. PubMed ID: 1761448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
    Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime.
    Ruiz-Carretero P; Merino-Sanjuán M; Nácher A; Casabó VG
    Eur J Pharm Sci; 2004 Feb; 21(2-3):217-23. PubMed ID: 14757493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of pharmacokinetic/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine.
    Ibar-Bariain M; Rodríguez-Gascón A; Isla A; Solinís MA; Canut-Blasco A
    Rev Esp Quimioter; 2019 Apr; 32(2):121-129. PubMed ID: 30727714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.